Israel, 20,859 patient vitamin D prophylaxis study: 13% lower hospitalization [p=0.003] https://c19p.org/israel2
copied to clipboard
Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population
et al., Epidemiology and Global Health Microbiology and Infectious Disease, doi:10.7554/eLife.68165
Case control study examining medication usage with a healthcare database in Israel, showing lower risk of hospitalization with vitamin D (defined as being picked up within 35 days prior to PCR+). Other patients may have acquired vitamin D supplements outside of the healthcare system.
|
risk of hospitalization, 13.1% lower, OR 0.87, p = 0.003, treatment 737 of 6,953 (10.6%) cases,
1,669 of 13,906 (12.0%) controls, NNT 33, case control OR, PCR+, cohort 2.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Israel et al., 7/27/2021, retrospective, Israel, Middle East, peer-reviewed, 10 authors, dosage not specified.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.